TY - JOUR
T1 - The 4Ps of breast cancer chemoprevention
T2 - Putting proven principles into practice
AU - Jordan, V. Craig
N1 - Publisher Copyright:
© 2017 AACR.
PY - 2017/4
Y1 - 2017/4
N2 - The pioneering Royal Marsden Tamoxifen Prevention Trial recruited 2,471 eligible high-risk women to be randomized to either placebo or tamoxifen (20 mg daily) for 8 years. Breast cancer incidence was evaluated at a median of 18.4 years from the start of the study. There was a 32% reduction in estrogen/ progesterone receptor (ER/PR)-positive breast cancers after tamoxifen treatment finished. Translational research, to study "the good, the bad, and the ugly of tamoxifen" in the 1980s, subsequently ensured women's safety from possible increases in osteoperosis, coronary heart disease, and endometrial cancer. Other tamoxifen chemoprevention trials followed. The result of laboratory research was the unanticipated discovery of raloxifene to prevent osteoporosis and breast cancer at the same time. A new group of medicines, now known as selective ER modulators, was established. Indeed, the ability to prevent or delay multiple diseases with a single cheap medicine has the potential to alleviate pressure on health care systems that are overwhelmed. It is a priority to educate physicians appropriately to apply recommended proven medicines as preventives.
AB - The pioneering Royal Marsden Tamoxifen Prevention Trial recruited 2,471 eligible high-risk women to be randomized to either placebo or tamoxifen (20 mg daily) for 8 years. Breast cancer incidence was evaluated at a median of 18.4 years from the start of the study. There was a 32% reduction in estrogen/ progesterone receptor (ER/PR)-positive breast cancers after tamoxifen treatment finished. Translational research, to study "the good, the bad, and the ugly of tamoxifen" in the 1980s, subsequently ensured women's safety from possible increases in osteoperosis, coronary heart disease, and endometrial cancer. Other tamoxifen chemoprevention trials followed. The result of laboratory research was the unanticipated discovery of raloxifene to prevent osteoporosis and breast cancer at the same time. A new group of medicines, now known as selective ER modulators, was established. Indeed, the ability to prevent or delay multiple diseases with a single cheap medicine has the potential to alleviate pressure on health care systems that are overwhelmed. It is a priority to educate physicians appropriately to apply recommended proven medicines as preventives.
UR - http://www.scopus.com/inward/record.url?scp=85017510142&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85017510142&partnerID=8YFLogxK
U2 - 10.1158/1940-6207.CAPR-17-0026
DO - 10.1158/1940-6207.CAPR-17-0026
M3 - Review article
C2 - 28246081
AN - SCOPUS:85017510142
SN - 1940-6207
VL - 10
SP - 219
EP - 222
JO - Cancer Prevention Research
JF - Cancer Prevention Research
IS - 4
ER -